{
    "id": 1178,
    "fullName": "EGFR mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR mut indicates an unspecified mutation in the EGFR gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "mutant",
    "createDate": "07/28/2014",
    "updateDate": "01/24/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3358,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 22% (22/58), stable disease in 47% (27/58), and progressive disease in 31% (18/58) of non-small cell lung carcinoma patients harboring uncommon EGFR mutations (PMID: 26354527).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3736,
                    "pubMedId": 26354527,
                    "title": "Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26354527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8425,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6652,
                    "pubMedId": 27225694,
                    "title": "EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225694"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18070,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15983,
                    "pubMedId": 30915273,
                    "title": "Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30915273"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8426,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6652,
                    "pubMedId": 27225694,
                    "title": "EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225694"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9038,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 4860,
                "therapyName": "Erlotinib + S63845",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2556,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Alunbrig (brigatinib) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including NSCLC patients harboring EGFR mutations (J Clin Oncol 31, 2013 (suppl; abstr 8031)).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3286,
                    "pubMedId": null,
                    "title": "First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.",
                    "url": "http://meetinglibrary.asco.org/content/114967-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3260,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Poziotinib (HM781-36B) displayed modest efficacy in lung adenocarcinoma patients with mutant EGFR (J Clin Oncol 33, 2015 (suppl; abstr 8085).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3700,
                    "pubMedId": null,
                    "title": "A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.",
                    "url": "http://meetinglibrary.asco.org/content/153342-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7709,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (MISSION), treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival (OS, 13.9 vs 6.5 mo, HR=0.48, p=0.002) and progression-free survival (PFS, 2.7 vs 1.4 mo, HR=0.27, p<0.001) when compared to placebo, and biomarker treatment interaction analysis indicated positive interaction between EGFR and OS (p=0.023) and PFS (p=0.015) (PMID: 26743856; NCT00863746).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6454,
                    "pubMedId": 26743856,
                    "title": "Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743856"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16339,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (ABC), treatment with Gilotrif (afatinib) plus Avastin (bevacizumab) resulted in an overall response rate (ORR) of 18.8% (6/32) and stable disease in 71.9% (23/32), a median progression-free survival (mPFS) of 6.3 mo, and median overall survival was not reached in non-small cell lung cancer patients with acquired resistance to EGFR inhibitor therapy, with an ORR of 14.3% and mPFS of 6.3 mo. in patients with EGFR T790M, and 22.2% and 7.1 mo. in patients without T790M (PMID: 30192383).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 8003,
                "therapyName": "Afatinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14460,
                    "pubMedId": 30192383,
                    "title": "Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30192383"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6997,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ASP8273 treatment resulted in partial response in 36% (16/45) and stable disease in 27% (12/45) of non-small cell lung carcinoma patients harboring EGFR mutations, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6005,
                    "pubMedId": null,
                    "title": "Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.",
                    "url": "http://meetinglibrary.asco.org/content/162561-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8427,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1356,
                "therapyName": "Durvalumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6652,
                    "pubMedId": 27225694,
                    "title": "EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225694"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13976,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ZODIAC), Caprelsa (vandetanib) and Taxotere (docetaxel) combination treatment resulted in improved progression-free survival (HR=0.51), overall survival (HR=0.46), and objective response (odd ratio=3.34) in non-small cell lung cancer patients harboring EGFR mutations compared to the overall study population (PMID: 25057173; NCT00312377).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 2935,
                "therapyName": "Docetaxel + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3279,
                    "pubMedId": 25057173,
                    "title": "EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25057173"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12960,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines for patients with EGFR mutant non-small cell lung cancer who have progressive leptomeningeal disease (NCCN.org).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16141,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MyPathway), Tarceva (erlotinib) treatment resulted in partial response in a patient with urethral adenocarcinoma harboring an EGFR mutation (PMID: 29320312; NCT02091141).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4910,
                "name": "urethra adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13171,
                    "pubMedId": 29320312,
                    "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19995,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Tarceva (erlotinib) and Cyramza (ramucirumab) is included in guidelines for non-small cell lung cancer patients with EGFR mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 8339,
                "therapyName": "Erlotinib + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11638,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, 87.5% (7/8) of solid tumor patients harboring EGFR alterations experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9671,
                    "pubMedId": 28351930,
                    "title": "Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351930"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6345,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients with compound EGFR mutations had inferior overall survival when compared to patients with single EGFR mutations (PMID: 26785607), suggesting that the presence of compound EGFR mutations may be have prognostic significance in lung adenocarcinoma.",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5534,
                    "pubMedId": 26785607,
                    "title": "Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26785607"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4408,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase IIa clinical trial, BMS-690514 demonstrated safety and preliminary anti-tumor activity in patients with non-small cell lung cancer, with patients harboring EGFR mutations achieving a disease control rate (DCR) of 70% (7/10), compared to a DCR of 29% (6/21) in EGFR-wild type patients (PMID: 23490650).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 685,
                "therapyName": "BMS-690514",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 78,
                    "pubMedId": 23490650,
                    "title": "Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23490650"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 22,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 852,
                "therapyName": "Pelitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1088,
                    "pubMedId": 16364494,
                    "title": "EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16364494"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 308,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 157,
                    "pubMedId": 24065731,
                    "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24065731"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17243,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (TATTON), Tagrisso (osimertinib) and Selumetinib (AZD6244) combination therapy resulted in partial response in 42% (15/36) and stable disease in 39% (14/36) of patients with EGFR-mutant non-small cell lung cancer in the dose-finding arm, and partial response in 34% (16/47) and stable disease in 23% (11/47) of patients in the dose expansion arm (AACR Annual Meeting 2019, Abstract CT034).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15258,
                    "pubMedId": null,
                    "title": "Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9828"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12020,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of DS-1205b and Tarceva (erlotinib) delayed the onset of therapeutic resistance compared to Tarceva (erlotinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model, and overcame resistance to Tarceva (erlotinib) in a Tarceva (erlotinib)-resistant xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 6232,
                "therapyName": "DS-1205b + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9970,
                    "pubMedId": null,
                    "title": "DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model",
                    "url": "http://www.poster-submission.com/esmo2017/visitors/eposter/34996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12019,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of DS-1205b and Tagrisso (osimertinib) delayed the onset of therapeutic resistance compared to Tagrisso (osimertinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 6231,
                "therapyName": "DS-1205b + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9970,
                    "pubMedId": null,
                    "title": "DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model",
                    "url": "http://www.poster-submission.com/esmo2017/visitors/eposter/34996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8428,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6652,
                    "pubMedId": 27225694,
                    "title": "EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27225694"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21315,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with the combination of Avastin (bevacizumab) with Paraplatin (carboplatin) and Alimta (pemetrexed) in non-squamous non-small cell lung cancer patients harboring an EGFR mutation prolonged progression-free survival (10.5 vs 6.6 months) and improved the overall response rate (54%, 12/22 vs 36%, 12/35) compared to patients harboring wild-type EGFR (PMID: 32088115).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 9598,
                "therapyName": "Bevacizumab + Carboplatin + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18628,
                    "pubMedId": 32088115,
                    "title": "Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32088115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19996,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Tarceva (erlotinib) and Avastin (bevacizumab) is included in guidelines as a first-line therapy for non-squamous non-small cell lung cancer patients with EGFR mutations (NCCN.org).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 4957,
                "therapyName": "NGI-1",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7042,
                    "pubMedId": 27694802,
                    "title": "Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2421,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545).",
            "molecularProfile": {
                "id": 1202,
                "profileName": "EGFR mutant"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3045,
                    "pubMedId": 20215545,
                    "title": "Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20215545"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in EGFR mutant NSCLC cell lines resulted in resistance to gefitinib or erlotinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2648,
                "profileName": "EGFR mut MED12 dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1536,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in EGFR mutant NSCLC cell lines resulted in resistance to gefitinib or erlotinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2648,
                "profileName": "EGFR mut MED12 dec exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3542,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",
            "molecularProfile": {
                "id": 13351,
                "profileName": "EGFR mut FGFR1 wild-type"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 311,
                    "pubMedId": 22238366,
                    "title": "Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22238366"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5396,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, OPB-51602 treatment resulted in partial response/stable disease in 24% (6/25) of non-small cell lung cancer patients, 83% (5/6) of patients responded harbored EGFR mutations and were positive for Stat3 (J Clin Oncol 32:5s, 2014 (suppl; abstr 8028)).",
            "molecularProfile": {
                "id": 20857,
                "profileName": "EGFR mut STAT3 pos"
            },
            "therapy": {
                "id": 3851,
                "therapyName": "OPB-51602",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5044,
                    "pubMedId": null,
                    "title": "Extended cohort study of OPB51602, a novel inhibitor of STAT3/5 activation, in non-small cell lung carcinoma.",
                    "url": "http://meetinglibrary.asco.org/content/127674-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6998,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, non-small cell lung cancer patients harboring both EGFR and TP53 mutations demonstrated a disease control rate (DCR) of 70.3% (26/37) following first-line treatment with an EGFR inhibitor such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib), compared to a DCR of 88.2% (75/85) in TP53 wild-type, EGFR-mutant patients (PMID: 27780855).",
            "molecularProfile": {
                "id": 24178,
                "profileName": "EGFR mut TP53 mut"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11253,
                    "pubMedId": 27780855,
                    "title": "Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780855"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6999,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR-mutant non-small cell lung cancer patients with TP53 exon 8 mutations demonstrated decreased disease control rate (42%, 5/12 vs 87%, 97/111), shorter median progression-free survival (4.2 vs 12.5 mo) and median overall survival (16.2 vs 32.3 mo) with first-line EGFR tyrosine kinase inhibitor treatment (such as Iressa (gefitinib), Tarceva (erlotinib), Gilotrif (afatinib), or Vizimpro (dacomitinib)), compared to TP53 exon 8 wild-type patients (PMID: 27780855).",
            "molecularProfile": {
                "id": 24179,
                "profileName": "EGFR mut TP53 exon8"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11253,
                    "pubMedId": 27780855,
                    "title": "Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780855"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9243,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring an EGFR mutation and decreased expression of PAK1 demonstrated sensitivity to Iressa (gefitinib) in culture, resulting in decreased cell viability (PMID: 27178741).",
            "molecularProfile": {
                "id": 26793,
                "profileName": "EGFR mut PAK1 dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9270,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung carcinoma cell line harboring an EGFR mutation and over expressing PAK1 demonstrated sensitivity to LY294002, resulting in decreased cell viability and reduced signaling of the PI3K pathway (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9272,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with IPA-3, resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4960,
                "therapyName": "Gefitinib + IPA-3",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring an EGFR mutation and over expressing PAK1 demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with Perifosine, resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4959,
                "therapyName": "Gefitinib + Perifosine",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9273,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an Iressa (gefitinib) resistant non-small cell lung cancer cell line xenograft model harboring an EGFR mutation and over expressing PAK1 demonstrated restored sensitivity to Iressa (gefitinib) when combined with Obatoclax (GX015-070), resulting in almost complete suppression of tumor burden (PMID: 27178741).",
            "molecularProfile": {
                "id": 26795,
                "profileName": "EGFR mut PAK1 over exp"
            },
            "therapy": {
                "id": 4961,
                "therapyName": "Gefitinib + Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7046,
                    "pubMedId": 27178741,
                    "title": "PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27178741"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9528,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated sensitivity to the combination of Iressa (gefitinib) and Cometriq (Cabometyx, cabozantinib) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 5064,
                "therapyName": "Cabozantinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9525,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9527,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET demonstrated sensitivity to the combination of Iressa (gefitinib) and Savolitinib (AZD6094) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26885,
                "profileName": "TPR - MET EGFR mut"
            },
            "therapy": {
                "id": 5063,
                "therapyName": "Gefitinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9526,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated resistance to Iressa (gefitinib) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9529,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated sensitivity to the combination of Iressa (gefitinib) and Cometriq (Cabometyx, cabozantinib) in culture, resulting in inhibition of cell growth (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 5064,
                "therapyName": "Cabozantinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9530,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR mutation and expressing TPR-MET and MET D1228V demonstrated resistance to the combination of Iressa (gefitinib) and Savolitinib (AZD6094) in culture (PMID: 27694386).",
            "molecularProfile": {
                "id": 26886,
                "profileName": "TPR - MET MET D1228V EGFR mut"
            },
            "therapy": {
                "id": 5063,
                "therapyName": "Gefitinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11341,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).",
            "molecularProfile": {
                "id": 27962,
                "profileName": "EGFR T790M EGFR mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9243,
                    "pubMedId": 28407039,
                    "title": "Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28407039"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11342,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitor therapy resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.37, p=0.084) in EGFR mutant non-small cell lung cancer patients with more than 1% CD274 (PD-L1) expression compared to patients with less than 1% CD274 (PD-L1) expression (PMID: 28407039).",
            "molecularProfile": {
                "id": 27963,
                "profileName": "CD274 pos EGFR mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9243,
                    "pubMedId": 28407039,
                    "title": "Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28407039"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 6373,
                "therapyName": "EMD 1214063 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17247,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (TATTON), combination of Tagrisso (osimertinib) and Savolitinib (AZD6094) resulted in an objective response rate (ORR) of 48% (66/138), a disease control rate (DCR) of 83% (115/138), and a median progression-free survival (mPFS) of 7.6 months in patients with EGFR-mutant, MET-amplified non-small cell lung cancer after progression on EGFR inhibitors, and an ORR of 64% (23/36), DCR of 92% (33/36), a mPFS of 9.1 months in EGFR T790M-negative patients (PMID: 32027846; NCT02143466).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17906,
                    "pubMedId": 32027846,
                    "title": "Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32027846"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15164,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) treatment resulted in partial response (PR) in 50% (4/8) of patients with EGFR mutant non-small cell lung cancer that acquired MET amplification after EGFR TKI therapy, although the response was short-lived, with a median progression-free survival of 3.5 months in patients achieved PR (PMID: 30268451).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15079,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Capmatinib (INC280) and Iressa (gefitinib) combination treatment resulted in an objective response rate of 27% (43/161) in non-small cell lung cancer patients harboring EGFR mutations and MET dysregulation (amplification or overexpression), with an objective response rate of 47% in Phase II patients with a MET gene copy number greater than 6 (PMID: 30156984).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 7415,
                "therapyName": "Capmatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12626,
                    "pubMedId": 30156984,
                    "title": "Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30156984"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12015,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of CRKL amplification was identified in an EGFR-mutant non-small cell lung carcinoma patient who developed progressive disease after treatment with Tarceva (erlotinib) (PMID: 22586683).",
            "molecularProfile": {
                "id": 31786,
                "profileName": "CRKL amp EGFR mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABX9xx inhibited Egfr and Met downstream signaling in several lung cancer cell lines harboring both EGFR and MET mutations in culture (AACR Annual Meeting 2019, Abstract 4830).",
            "molecularProfile": {
                "id": 32522,
                "profileName": "EGFR mut MET mut"
            },
            "therapy": {
                "id": 8471,
                "therapyName": "ABX9xx",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15402,
                    "pubMedId": null,
                    "title": "ABX9xx: A bispecific centyrin that synergizes to attenuate intracellular signaling in Met/EGFR positive tumors",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/3146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20385,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DFX117 treatment inhibited Pi3k/Akt and Met signaling, cell viability, and colony formation, and induced apoptosis and cell cycle arrest in a non-small lung carcinoma cell line harboring MET amplification and mutations in PIK3CA and EGFR in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31060329).",
            "molecularProfile": {
                "id": 35157,
                "profileName": "EGFR mut MET amp PIK3CA mut"
            },
            "therapy": {
                "id": 9339,
                "therapyName": "DFX117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17823,
                    "pubMedId": 31060329,
                    "title": "Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3K\u03b1 in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31060329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20500,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (TATTON), combination of Tagrisso (osimertinib) and Savolitinib (AZD6094) resulted in an objective response rate (ORR) of 67% (12/18, 12 partial response), a disease control rate (DCR) of 100% (18/18), and a median progression-free survival of 11.0 months in patients with EGFR-mutant, EGFR T790M-positive, MET-amplified non-small cell lung cancer after progression on first/second generation EGFR inhibitors (PMID: 32027846; NCT02143466).",
            "molecularProfile": {
                "id": 35213,
                "profileName": "EGFR T790M EGFR mut MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17906,
                    "pubMedId": 32027846,
                    "title": "Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32027846"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1202,
            "profileName": "EGFR mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2648,
            "profileName": "EGFR mut MED12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13351,
            "profileName": "EGFR mut FGFR1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20857,
            "profileName": "EGFR mut STAT3 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24178,
            "profileName": "EGFR mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24179,
            "profileName": "EGFR mut TP53 exon8",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24180,
            "profileName": "EGFR mut TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26793,
            "profileName": "EGFR mut PAK1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26795,
            "profileName": "EGFR mut PAK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26796,
            "profileName": "EGFR mut PAK1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26885,
            "profileName": "TPR - MET EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26886,
            "profileName": "TPR - MET MET D1228V EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27962,
            "profileName": "EGFR T790M EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27963,
            "profileName": "CD274 pos EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28383,
            "profileName": "CRKL over exp EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28588,
            "profileName": "EGFR mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31786,
            "profileName": "CRKL amp EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32522,
            "profileName": "EGFR mut MET mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35157,
            "profileName": "EGFR mut MET amp PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35213,
            "profileName": "EGFR T790M EGFR mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}